Plain-English translation of NCT06964087 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new medication given by injection under the skin, to see if it can help preserve the body's ability to produce its own insulin in people with type 1 diabetes. The study has three parts: first, researchers will test different doses to find the safest and best amount; then, they will test the chosen dose in two groups of patients—some diagnosed 1 to 10 years ago, and others diagnosed within the past year. This medication is designed to work with the body's immune system to protect the insulin-producing cells that are damaged in type 1 diabetes.
In type 1 diabetes, the immune system mistakenly attacks the cells that make insulin. If this medication can help protect those remaining cells early on, it might help patients produce more of their own insulin naturally, which could make managing their diabetes easier and improve their long-term health.
You likely qualify if…
You likely don't qualify if…
The study lasts about one year and is divided into phases. In the first phase, a small group of patients will receive injections of the medication under the skin three times per week for two weeks at different dose levels. After researchers find the safest dose, the second and third phases test that dose over the full year in larger groups of patients—some will receive the medication, and others will receive a placebo (inactive injection) so doctors can compare results. Throughout the trial, you will wear a continuous glucose monitor, have regular blood tests, and visit the clinic for checkups.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States